About LUMICKS
LUMICKS is a company based in Amsterdam (Netherlands) founded in 2014 by Andrea Candelli. LUMICKS has raised $93.38 million across 10 funding rounds from investors including T. Rowe Price, European Investment Bank and Farallon Capital Management. LUMICKS offers products and services including Cell Avidity, Dynamic Single-Molecule, Avidion, C-Trap, and z-Movi. LUMICKS operates in a competitive market with competitors including 10X Genomics, Mission Bio, Cellares, LevitasBio and Rebus Biosystems, among others.
- Headquarter Amsterdam, Netherlands
- Founders Andrea Candelli
-
Sectors
HealthcareTechnology
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$93.38 M (USD)
in 10 rounds
-
Latest Funding Round
$21.87 M (USD), Debt – Venture
Oct 11, 2024
-
Investors
T. Rowe Price
& 10 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of LUMICKS
LUMICKS offers a comprehensive portfolio of products and services, including Cell Avidity, Dynamic Single-Molecule, Avidion, C-Trap, and z-Movi.
Measures binding strength in cellular contexts for research applications.
Visualizes and analyzes molecular mechanisms in real-time.
Enables next-generation cell avidity analysis for studies.
Reimagines interactions through single-molecule manipulation.
Supports small-scale cell avidity studies effectively.
Offers white-glove support for cell avidity experiments.
People of LUMICKS
Unlock access to complete
Unlock access to complete
Funding Insights of LUMICKS
LUMICKS has successfully raised a total of $93.38M across 10 strategic funding rounds. The most recent funding activity was a Debt – Venture round of $21.87 million completed in October 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in LUMICKS
LUMICKS has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include T. Rowe Price, European Investment Bank and Farallon Capital Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Finance and advisory services for infrastructure projects are provided.
|
Locked | Locked | Locked | |
|
Government agency and accelerator focusing on innovative startups and SMEs
|
Locked | Locked | Locked | |
|
Multiple investment strategies are pursued by this hedge fund.
|
Locked | Locked | Locked |
Investor details for LUMICKS
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by LUMICKS
Investment portfolio details for LUMICKS
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - LUMICKS
Detailed financials for LUMICKS
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Lumicks Comparisons
Peer comparison for LUMICKS
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of LUMICKS
LUMICKS operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as 10X Genomics, Mission Bio, Cellares, LevitasBio and Rebus Biosystems, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Instrument systems for genomic research and sequencing libraries are developed.
|
|
| Locked | Locked | Locked |
Single-cell multi-omics platform is provided for genotypic and phenotypic analysis.
|
|
| Locked | Locked | Locked |
Medical devices for cell-based therapy manufacturing are produced.
|
|
| Locked | Locked | Locked |
Single-cell imaging platform developed via magnetic levitation technology.
|
|
| Locked | Locked | Locked |
An imaging system for single-cell gene analysis is developed.
|
Detailed competitors of LUMICKS
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Lumicks
Complete news archive for LUMICKS
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about LUMICKS
LUMICKS was founded in 2014 and raised its 1st funding round 1 year after it was founded.
LUMICKS is headquartered in Amsterdam, Netherlands.
LUMICKS is a funded company, having raised a total of $93.38M across 10 funding rounds to date.
Manufacturer of optical tweezers for single-molecule analysis instruments. The product portfolio of the company includes C-Trap, an integrated system with optical tweezers, a confocal microscope, and a microfluidic system to analyze protein folding, DNA repair, DNA organization, Protein polymer, and filaments. Its product, AFS-acoustic force spectroscopy (a single molecule manipulation system), and u-Flux (an integrated microfluidic system) are used in performing experiments in a laminar flow environment.
LUMICKS's top competitors include 10X Genomics, Mission Bio and Cellares.
LUMICKS offers Cell Avidity, Dynamic Single-Molecule, Avidion, C-Trap, and 2 more products and services.
LUMICKS has 11 investors. Key investors include T. Rowe Price, European Investment Bank, Farallon Capital Management, European Union, and SoftBank Vision Fund.